Recently introduced targeted therapies for neuroblastoma patients include the small molecule inhibitor Crizotinib, which targets the receptor tyrosine kinase Anaplastic Lymphoma Kinase (ALK) and was well tolerated in a recent Phase 1 dose-escalation trial (31). The gene discussed is ALK; the disease is neuroblastoma.